Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.
Quantitative electrophysiologic assessments are sensitive and useful indices of clinical state, and they are valuable in evaluating brain electrical activity before and after recombinant human erythropoietin (r-HuEPO) treatment. To study the hypothesis that, theoretically, anemia might be a cause of brain dysfunction in uremia, the authors assessed 18 patients (10 men and 8 women) on hemodialysis (RDT, age range, 35-58 years) before treatment (T1), and after 12 weeks (T2) and 24 weeks (T3) of r-HuEPO treatment, utilizing the following electrophysiologic tests: visual evoked potentials (VEP), brainstem auditory evoked responses (BAER), and somatosensory evoked potentials (SEP). The r-HuEPO was injected subcutaneously two times a week after RDT to produce hematocrit (Hct) levels of 30-35%. This drug induced a decrement of latency in P100 VEP (134.2 +/- 7.9 msec in T1 versus 116.5 +/- 6.9 msec in T2, p < 0.001, and versus 107.6 +/- 5.7 msec in T3, p < 0.005) and in the four main components of BAER. The most significant SEP changes were P27-N35 from peroneal nerve (p < 0.01), as an augmentation of SEP amplitude. Correction of anemia with r-HuEPO leads to a significant improvement in brain function in patients on RDT. The increased Hct level leads to enhanced brain oxygen delivery, directly improving brain metabolism. When the Hct rises, cerebral blood flow falls from high levels to normal, decreasing delivery of uremic "toxins" to the brain. The decrease in cerebral blood flow may decrease intracranial pressure and, in this way, may exert its beneficial effects by a rheologic pathway.
Di Paolo
B
B
Department of Nephrology, University of Chieti, Italy.
Di Liberato
L
L
Fiederling
B
B
Catucci
G
G
Bucciarelli
S
S
Paolantonio
L
L
Albertazzi
A
A
D000328:Adult; D000740:Anemia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000503:physiopathology*; D002560:Cerebrovascular Circulation; D004594:Electrophysiology; D004921:Erythropoietin / Q000627:therapeutic use*; D016057:Evoked Potentials, Auditory, Brain Stem; D005073:Evoked Potentials, Somatosensory; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000378:metabolism; D006435:Renal Dialysis; D014511:Uremia / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy
D004921:Erythropoietin; D010100:Oxygen